Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2021-08-11 Investor Presentation
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Präsentation H1 2021
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Driving growth & Getting ready for launch' and 'Welcome to H1 2021'. It contains comprehensive financial performance data, segment information, balance sheet details, and strategic outlooks for the first half of the fiscal year 2021. It is clearly an investor-facing presentation summarizing interim financial results and business strategy, which fits the definition of an Investor Presentation (IP). H1 2021
2021-08-11 English
Evotec SE to announce results for the first half-year 2021 on 11 August 2021
Report Publication Announcement Classification · 99% confidence The document is a short news release dated August 4, 2021, announcing that Evotec SE will release its financial results for the first half-year 2021 on August 11, 2021, and will host a conference call and webcast to discuss them. This is not the actual financial report (which would be an IR or 10-K), nor is it the full transcript (CT). It is an announcement about the upcoming publication of results and the associated investor event details. This fits the definition of a Report Publication Announcement (RPA), which signals the timing of a report release, or potentially an Earnings Release (ER) if it contained the key highlights, but since it only announces the date of the results and call, RPA is the most precise fit for announcing the publication schedule. Given the content focuses entirely on scheduling the release and conference call, RPA is the best classification.
2021-08-04 English
Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough
Legal Proceedings Report Classification · 99% confidence The document is explicitly labeled as an "Ad-hoc" release dated August 3, 2021, disclosing "inside information acc. to Article 17 MAR". It announces positive Phase IIb clinical trial results for a drug candidate developed by Evotec and Bayer. This type of immediate, material, non-scheduled disclosure regarding study results, which is not a full financial report (like 10-K or IR) or a standard earnings release (ER), fits best under the general category for regulatory announcements that don't have a more specific code. While it contains study results, it is structured as a mandatory regulatory disclosure under MAR, making 'Regulatory Filings' (RNS) the most appropriate general classification, as it is not a transcript (CT), investor presentation (IP), or management discussion (MDA). Given the context of immediate regulatory disclosure of material, non-financial operational news, RNS is the best fit among the provided options.
2021-08-03 English
Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc' announcement dated August 2, 2021, detailing the confidential submission of a Draft Registration Statement on Form F-1 to the SEC for a proposed offering of American Depositary Shares (ADSs). This action relates directly to fundraising, capital structure changes, and seeking a listing on a US exchange (Nasdaq). This fits the definition of 'Capital/Financing Update' (CAP) as it concerns a proposed offering and sale of securities. It is not an ER (Earnings Release), IR (Interim Report), or 10-K (Annual Report). While it involves SEC filings, the core subject is the capital raising activity itself, making CAP the most specific fit over the general RNS.
2021-08-02 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights'. It details a 'Type of capital measure' which is a 'Conditional capital increase' and provides the 'New total number of voting rights'. This content directly relates to changes in the company's capital structure and the resulting voting power, which aligns best with the 'Capital/Financing Update' (CAP) category, as it announces a change affecting the capital structure via a conditional increase. While it involves voting rights, it is a specific capital action announcement, not the results of a shareholder vote (DVA) or a general regulatory filing (RNS). Given the focus on capital increase and total rights, CAP is the most precise fit.
2021-07-30 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports a change in the percentage of voting rights held by Impax Asset Management Group plc, crossing a threshold (3.02%). This directly corresponds to the definition of a major shareholding notification, which is classified under the code MRQ (Major Shareholding Notification). Although it mentions 'Voting Rights Announcements' in the header, MRQ is the more specific category for reporting ownership changes crossing thresholds, whereas DVA is for reporting the *results* of a vote.
2021-07-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.